In the case we report, this evidence-based rationale informed the therapeutic approach: the patient was treated with dasatinib, a BCR::ABL1-targeted TKI, as a preparatory strategy for allo-HSCT (as detailed in the Treatment section), reflecting current practice patterns for this high-risk leukemia subtype. This evidence concerns the gene BCR and leukemia.